The analgesic properties of myrrh (Commiphora myrrha) have been known since ancient times and depend on the presence of bioactive sesquiterpenes with furanodiene skeletons. MyrLiq® is a C. myrrha extract with a standardized content of curzerene, furanoeudesma-1,3-diene and lindestrene (12.31 ± 0.05 g kg-1, 18.84 ± 0.02 g kg-1 and 6.23 ± 0.01 g kg-1, respectively) and a high total furanodiene content (40.86 ± 0.78 g kg-1). In a pilot study, a balanced sample of 95 female and 89 male volunteers (with ages ranging from 18 to older than 60 years) exhibiting different pain pathologies, including headache, fever-dependent pain, joint pain, muscle aches, lower back pain and menstrual cramps, was divided into two groups. The experimental group received 1 capsule/day containing either 200 mg or 400 mg of MyrLiq® (corresponding to 8 mg and 16 mg of bioactive furanodienes, respectively) for 20 days, and the placebo group was given the same number of capsules with no MyrLiq®. A score was recorded for all volunteers based on their previous experience with prescribed analgesics. For the male volunteers, pain alleviation was obtained with 400 mg of MyrLiq®/day for almost all pathologies, whereas for female volunteers, alleviation of lower back pain and fever-dependent pain was observed with only 200 mg of MyrLiq®/day. These results indicate that MyrLiq® has significant analgesic properties.

A pilot study on bioactive constituents and analgesic effects of MyrLiq®, a Commiphora myrrha extract with a high furanodiene content

OCCHIPINTI, Andrea;BARBERO, Francesca;MAFFEI, Massimo Emilio
Last
2017-01-01

Abstract

The analgesic properties of myrrh (Commiphora myrrha) have been known since ancient times and depend on the presence of bioactive sesquiterpenes with furanodiene skeletons. MyrLiq® is a C. myrrha extract with a standardized content of curzerene, furanoeudesma-1,3-diene and lindestrene (12.31 ± 0.05 g kg-1, 18.84 ± 0.02 g kg-1 and 6.23 ± 0.01 g kg-1, respectively) and a high total furanodiene content (40.86 ± 0.78 g kg-1). In a pilot study, a balanced sample of 95 female and 89 male volunteers (with ages ranging from 18 to older than 60 years) exhibiting different pain pathologies, including headache, fever-dependent pain, joint pain, muscle aches, lower back pain and menstrual cramps, was divided into two groups. The experimental group received 1 capsule/day containing either 200 mg or 400 mg of MyrLiq® (corresponding to 8 mg and 16 mg of bioactive furanodienes, respectively) for 20 days, and the placebo group was given the same number of capsules with no MyrLiq®. A score was recorded for all volunteers based on their previous experience with prescribed analgesics. For the male volunteers, pain alleviation was obtained with 400 mg of MyrLiq®/day for almost all pathologies, whereas for female volunteers, alleviation of lower back pain and fever-dependent pain was observed with only 200 mg of MyrLiq®/day. These results indicate that MyrLiq® has significant analgesic properties.
2017
2017
1
11
https://www.hindawi.com/journals/bmri/2017/3804356/
analgesic, Myrrh, Commiphora myrrha, furanodienes
Germano, Antonio; Occhipinti, Andrea; Barbero, Francesca; Maffei, Massimo Emilio
File in questo prodotto:
File Dimensione Formato  
2017 Myrliq analgesic effects BMRI.pdf

Accesso aperto

Descrizione: articolo principale
Tipo di file: PDF EDITORIALE
Dimensione 1.8 MB
Formato Adobe PDF
1.8 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1638133
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 36
  • ???jsp.display-item.citation.isi??? 26
social impact